— Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million — Generated $27.9 million of net income in the third quarter of 2025 — Completed enrollment in the dose escalation phase and enrolled the first patient in the dose […]
NASHVILLE, TN / ACCESS Newswire / November 4, 2025 / First Acceptance Corporation (OTCQX:FACO) today reported its financial results for the quarter ended September 30, 2025. A quarterly report can be found at www.otcmarkets.com/stock/FACO/disclosure. Revenues for the three months ended September 30, 2025 increased 9% to $140.7 million from $129.3 million in the same period
Iridium Communications Inc. (Nasdaq: IRDM) (“Iridium”), a leading provider of global voice, data and PNT satellite services,today announced that Company executives would participate in upcoming investor conferences: https://mma.prnewswire.com/media/1394616/IRIDIUM_Logo.jpg — The Deutsche Bank Global Space Summit on Wednesday, November 19, 2025. — The Bank of America Leveraged Finance Conference on Tuesday, December 2, 2025. — The
Initiated US and EU launch of Sephience™ (sepiapterin) – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – Robust Q3 performance with total revenue of $211M – Full-year 2025 revenue guidance narrowed to $750 – $800M – PTC Therapeutics, Inc., (NASDAQ: PTCT) today
New Phase 1 PK Data Support Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration DA-1726 Achieves Superior Lipid-Lowering Effects and Comparable Weight Loss to Pemvidutide in Pre-clinical Models MetaVia Inc. (Nasdaq: MTVA),a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will present new Phase 1 and pre-clinical data on
https://mma.prnewswire.com/media/231466/axon_logo.jpg — Software & Services revenue grows 41% to $305 million — Annual recurring revenue grows 41% to $1.3 billion — Net loss was $2 million, with non-GAAP net income of $98 million and Adjusted EBITDA of $177 million — Raises full year revenue outlook to approximately $2.74 billion, 31% annual growth, up from $2.65
Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: https://mma.prnewswire.com/media/1063194/inhibrx_Logo.jpg 21st Annual Industry/Academia Precision Oncology & Radmed SymposiumNovember 5th, 2025 – La Jolla, California Title:DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal
Thirty-Ninth Consecutive Period of Record Revenue AudioEye, Inc.(Nasdaq: AEYE) (“AudioEye” or the “Company”), the industry-leading digital accessibility company,reported financial results for the third quarter ended September 30, 2025. https://mma.prnewswire.com/media/1470477/AudioEye_v3_Logo.jpg “AudioEye achieved another record quarter with over $10.2 million in revenue, record adjusted EBITDA and margin, and strong GAAP results,” said AudioEye CEO David Moradi. “In
Third quarter2025 GAAP diluted loss per share of$(2.41) Third quarter2025 adjusted airline-only loss per share of $(1.64)(1)(2) Third quarter2025 adjusted loss per share of $(2.09)(1)(2) Allegiant Travel Company (NASDAQ: ALGT) today reported the below financial results for third quarter 2025, as well as comparisons to the prior year. https://mma.prnewswire.com/media/486546/AllegiantLogoBlue__NoTagline_2014_Logo.jpg “The airline has always been Allegiant's
(NASDAQ:FLYW), Third Quarter Revenue Increased 27.6% Year-over-Year Third Quarter Revenue Less Ancillary Services Increased 28.2% Year-over-Year Previous Fiscal Year 2025 revenue guidance raised by 400 bps at midpoint, aEBITDA margin guidance raised by 75 bps at midpoint BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) — Flywire Corporation (Nasdaq: FLYW) (“Flywire” or the “Company”), a global payments